Flunarizine in vivo protects against endothelial cell damage induced by intravenous injection of citrate, CaCl2, or lactate in rats. Its effect is optimal at the low oral dose of 0.1 mg/kg, corresponding to the clinically used one. It lasts for at least 8 hours. Edema formation, platelet activation, and venostatic thrombosis subsequent to endothelial cell injury consequently are also in hibited by flunarizine. The compound does not affect platelet function, plasma coagulation or generation of PGI2 by vascular tissue and does not impair normal haemostasis at effective doses. As for its vascular and hemor rheological effects, the protection by flunarizine against endothelial injury may be related to its Ca2+-antagonistic properties.
Get full access to this article
View all access options for this article.
References
1.
Harker, L.A. , Ross, R., Glomset, J.A.: The role of endothelial cell injury and platelet response in atherogenesis. Thromb. Res., 39: 312, 1978.
2.
Harker, L.A. , Slichter, S.J., Scott, C.: Homocystinemia, vascular injury and arterial thrombosis. N. Engl. J. Med., 291: 537, 1974 .
3.
Minick, C.R. , Murphy, G.E.: Experimental induction of atherosclerosis by the synergy of allergic injury to arteries and lipid-rich diet. II. Effect of repeatedly injected foreign protein in rabbits fed a lipid-rich, cholesterol-poor diet. Am. J. Pathol., 73: 265, 1973.
4.
Baumgartner, H.R.: The subendothelial surface and thrombosis, in Thrombosis: Pathogenesis and Clinical Trials. Edited by E. Deutsch, K. M. Brinkhous, K. Lechner and S. Hinnom.Stuttgart, F. K. Schattauer-Verlag, 1974, p. 91.
5.
Moore, S., Friedman, R.J., Singal, D.P., et al.: Inhibition of injury-induced thromboatherosclerotic lesions by antiplatelet serum in rabbits. Thromb. Diath. Haemorrh. , 35: 70, 1976.
6.
Ross, R., Glomset, J., Kariya, B., et al.: A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle in vitro. Proc. Natl. Acad. Sci. USA, 71: 1207, 1974.
7.
Van Nueten, J.M., Wellens, D.: Mechanisms of vasodilatation and antivasoconstriction . Angiology, 30: 440, 1979.
8.
Emanuel, M.B. : Specific calcium antagonism on the treatment of peripheral vascular disease. Angiology, 30: 454, 1979.
9.
Domschky, K. , Nelson, M., Dammhayn, B., et al.: Flunarizine bei Patienten mit Zerebralen und Peripherer Mangeldurchblutung. Med. Welt, 28: 1062, 1977.
10.
Schetz, J., Bostoen, H., Clement, D., et al.: Flunarizine in chronic peripheral arterial disease. Curr. Ther. Res., 23: 121, 1978.
11.
Van Nueten, J.M., Van Beek, J., Janssen, P.A.J.: Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch. Int. Pharmacodyn. Ther., 232: 42, 1978.
12.
Van Nueten, J.M., Van Beek, J., Janssen P.A.J.: The vascular effects of flunarizine as compared with those of other clinically used vasoactive substances. Arzneim. Forsch., 28: 2882, 1978.
13.
Borgers, M. , Ghoos, E., Thoné, F., Van Nueten, J.M.: Effects of flunarizine in the distribution of calcium in vascular smooth muscle. Blood Vessels, 17: 123, 1980.
14.
De Clerck, F., Beerens, M., Thoné, F., et al.: The effect of flunarizine and other vasoactive compounds on the human RBC crenation and on the calcium-deposition induced by ionophore A 23187. Biorheology, 16: 522, 1979.
15.
De Cree, J. , De Cock, W., Geukens, H., et al.: The rheological effects of cinnarizine and flunarizine in normal and pathologic conditions. Angiology , 30: 505, 1979.
16.
Hladovec, J. , Rossmann, P.: Circulating endothelial cells isolated together with platelets and the experimental modification of their counts in rats. Thromb. Res.3: 665, 1973.
17.
Hladovec, J. , Svobodová, J., Rossmann, P.: Influence of citrate on platelet adhesion to the endothelial surface. Physiol. Bohemoslov., 1: 421, 1970.
18.
Hladovec, J.: A quantitative model of venous stasis thrombosis in rats. Physiol. Bohemoslov., 24: 551, 1975.
19.
Hladovec, J.: Experimental arterial throbosis in rats with continuous registration. Thromb. Diath. Haemorrh., 26: 407, 1971.
20.
De Clerck, F., Borgers, M., Vermylen, J., et al.: Human Platelet aggregation by Thrombofax®. An electron-microscopic study of the sequences of events. Scand. J. Haematol., 12: 93, 1974.
21.
De Clerck, F., VanGorp., L., Xhonneux, R.: Effect of lorcainide, a new antiarrhytmic compound, on the changes in heart rhythm induced by intravenous injection of adenosine-5'-diphosphate in rats. Arch. Int. Pharmacodyn. Ther., 231: 222, 1978 .
22.
De Clerck, F., Vermylen, J., Reneman, R.: Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. In vitro experiments. Arch. Int. Pharmacodyn. Ther., 216: 283, 1975.
23.
Villa, S., Mysliwiec, M., De Gaetano, G.: Prostacyclin and atherosclerosis in rats. Lancet1: 1216, 1977.
24.
Dacie, J.V., Lewis, S.M.: Practical Haematology. London, J. & A., Churchill Ltd., 1968.
25.
De Clerck, F., Goossens, J., Reneman, R.: Effects of antiinflammatory, anticoagulant and vasoactive compounds on tail bleeding time, whole blood coagulation time and platelet retention by glass beads. Thromb. Res., 8: 179, 1976.
26.
Zweifach, B.W. : Integrity of vascular endothelium. Adv. Microcirc., 9: 206. in Vascular Endothelium and Basement Membranes . Edited by B. M. Altura, Basel, S. Karger, 1980.
Cirilli, R. , Holiday, J.E., Fesperman, D.P., et al.: Antivascular endothelial cell antibody—its role in transplantation. Surgery, 81: 132, 1977.
29.
Gerrity, R.G. , Caplan, B.A., Richardsen, M., et al.: Endotoxin-induced endothelial injury and repair. I. Endothelial cell turnover in the aorta of the rabbit. Exp. Mol. Pathol., 23: 397, 1975.
30.
Harker, L.A. , Ross, R., Shichter, S.J., et al.: Hemocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J. Clin. Invest., 58: 731, 1976.
31.
Hladovec, J. : Circulating endothelial cells as a sign of vessel wall lesions. Physiol. Bohemoslov., 27: 140, 1978.
32.
Warren, B.A. , Khan, S.: The ultrastructure of the lysis of fibrin by endothelium in vitro. Br. J. Exp. Pathol., 35: 138, 1974.
33.
Harpel, P.C., Rosenberg, R.D.: Alpha-2-macroglobulin and antithrombin heparin cofactor: modulators of hemostatic and inflammatory reactions; in Progress in Hemostasis and Thrombosis , vol. 3. Edited by T. Spaet.New York, Grune & Stratton, 1976, p. 145.
34.
Maynard, J.R. , Heckman, C.A., Pitlick, F.A., et al.: Association of tissue factor activity with the surface of cultured cells. J.Clin. Invest., 55: 814, 1975.
35.
Jaffe, E.A. , Koyer, L.W., Nachman, R.I.: Synthesis of Von Willebrand factor by cultured human endothelial cells. Proc. Natl. Acad. Sci. USA, 71: 1906, 1974.
36.
Buonassisi, V., Root, M.: Enzymatic degradation of heparin-related mucopolysaccharides from the surface of endothelial cell cultures. Biochim. Biophys. Acta, 385: 1, 1975.
37.
Moncada, S. , Korbut, R., Bunting, S., et al.: Prostacyclin is a circulating hormone . Nature, 273: 767, 1978.
38.
Hladovec, J. : Influence of calcium antagonists on endothelium . Arzneim.-Forsch., 29: 1101, 1979.
39.
Clementi, F. , Palade, G.: Intestinal capillaries. II. Structural effects of EDTA and histamine. J. Cell Biol., 42: 706, 1969.
40.
Bridwell, C.R. : Identification and role of fibronectin in cultured bovine endothelial cells. Proc. Natl. Acad. Sci. USA, 75: 3273, 1978.
41.
Northover, B.J.: The membrane potential of vascular endothelial cells. Adv. Microcirc., 9: 195. in Vascular Endothelium and Basement Membranes." Edited by B. M. Altura. Basel, S. Karger, 1980.
42.
Van Nueten, J.M., Vanhoutte, P.M.: Improvement of tissue perfusion with inhibitors of calcium ion influx. Biochem. Pharmacol., 29: 479, 1980.
43.
Snoeckx, L. , Bruyneel, K., De Clerck, F., et al.: Electrically-induced coronary artery thrombosis in closed chest anaesthetized dogs. Evaluation of the method. Basic Res. Cardiol., 73: 241, 1978.
